Glenmark Life Sciences Limited (GLS.BO)

INR 1021.7

(-0.42%)

Market Cap (In INR)

125.19 Billion

Revenue (In INR)

22.83 Billion

Net Income (In INR)

4.7 Billion

Avg. Volume

21.61 Thousand

Currency
INR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
627.25-1335.0
PE
-
EPS
-
Beta Value
0.16
ISIN
INE03Q201024
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Yasir Yusufali Rawjee Ph.D.
Employee Count
-
Website
https://www.glenmarklifesciences.com
Ipo Date
2021-08-06
Details
Glenmark Life Sciences Limited engages in the development, manufacture, and supply of non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. It offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin, and Cilostazol for the treatment of cardiovascular disease; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for the treatment of central nervous system disease; Remogliflozin, Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for the treatment of diabetes; Etoricoxib, Lornoxicam, Zolmitriptan, and Frovatriptan for pain management; and Olaparib, Palbociclib, Enzalutamide, and Ruxolitinib for oncology treatment, as well as Atovaquone, an anti-parasitic and Adapalene, a dermatology product. The company also provides contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited operates as a subsidiary of Glenmark Pharmaceuticals Limited.